NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 1.660

-2.4%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: old 'n cranky who wrote (12784)	5/27/2020 10:16:54 AM
From: RoadyHD	Read Replies (3) of 12871

Given the nanoviricide MOA and the fact that hCoV-NL63 is a CoV cousin with the same receptor target, it was appropriate to use, and the results are very useful. Determining which ligands worked on this cousin virus helped the company calibrate and confirm its computer models and narrow candidate ligands to the ones most likely to work on the SARS CoV-2 virus. This is the stuff biotechs do. This is good. And the next step is to test whether it actually does work on it. As for whether the company can do that test, attract collaboration, get credibility, and file an IND... Yes, it has a poor track record on that. That's why it is a nanocap. But we've got our candidate ligand, along with a full year's worth of capital. Let's see.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next